PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.02
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$221.75

22 Nov
2024

7.130

OPEN

$216.99

3.32%

HIGH

$224.65

172,734

LOW

$215.12

TARGET
$134.10 -39.5% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 79.3 102.7 xxx
DPS (cps) xxx 40.0 51.4 xxx
EPS Growth xxx 36.5% 29.6% xxx
DPS Growth xxx 33.3% 28.4% xxx
PE Ratio xxx N/A 215.9 xxx
Dividend Yield xxx N/A 0.2% xxx
Div Pay Ratio(%) xxx 50.5% 50.0% xxx

Dividend yield today if purchased 3 years ago: 0.67%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.18

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 22c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx79.3
DPS All xxxxxxxxxxxxxxx40.0
Sales/Revenue xxxxxxxxxxxxxxx161.5 M
Book Value Per Share xxxxxxxxxxxxxxx179.8
Net Operating Cash Flow xxxxxxxxxxxxxxx86.8 M
Net Profit Margin xxxxxxxxxxxxxxx51.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx50.72 %
Return on Invested Capital xxxxxxxxxxxxxxx50.30 %
Return on Assets xxxxxxxxxxxxxxx36.03 %
Return on Equity xxxxxxxxxxxxxxx50.72 %
Return on Total Capital xxxxxxxxxxxxxxx67.94 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx49.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx155 M
Price To Book Value xxxxxxxxxxxxxxx79.69

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx6.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.14 %
Cost of Goods Sold xxxxxxxxxxxxxxx39 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.4

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

15/08/2024

5

Sell

$100.00

-54.90%

FY24 profit from Pro Medicus is a 5% beat against the consensus forecast on better-than-expected operating margins, while revenue is in line, explains Citi.

Management still sees a "huge amount of runway ahead" and believes current operating margins of around 70% are sustainable.

The FY24 dividend of 40cps was a 28% year-on-year increase. The target rises to $100 from $95. The broker's Sell rating is kept on valuation.

FORECAST
Citi forecasts a full year FY25 dividend of 50.10 cents and EPS of 100.20 cents.
Citi forecasts a full year FY26 dividend of 64.10 cents and EPS of 128.30 cents.

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

3

xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Goldman Sachs

08/10/2024

1

Buy

$193.00

-12.97%

The contract terms between Pro Medicus and Mercy Health have been negotiated at a higher per-transaction cost and the contract duration increased to eight years from seven.

The new contract for $98m replaces the Visage Viewer $21m contract struck in April 2016, and the $15m for Open Archive in June 2018.

The industry norm is for a shorter extension, highlights Goldman Sachs. Overall, it's felt the extension is a reflection of the strong return on investment (ROI) generated via Visage despite its price premium relative to peers.

The pipeline remains healthy, believe the analysts. The Buy rating and $193 target are maintained.

FORECAST
Goldman Sachs forecasts a full year FY25 dividend of 54.10 cents and EPS of 104.00 cents.
Goldman Sachs forecasts a full year FY26 dividend of 68.00 cents and EPS of 133.00 cents.

Moelis

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Rudi’s View: The Importance Of ‘Quality’ Growth

Nov 21 2024 - Rudi's View
2
Rudi’s View: Knock. Knock. Volatility Is Back!

Nov 20 2024 - Rudi's View
3
Rudi’s View: A Rally With No Earnings Support

Nov 14 2024 - Rudi's View
4
Weekly Ratings, Targets, Forecast Changes – 08-11-24

Nov 11 2024 - Weekly Reports
5
Rudi’s View: Trump Returns, What Now?

Nov 07 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps